Dr. Alexander M. Schabauer, MD
Cardiology (Cardiovascular Disease Physician)
4150 Fifth Street
Rapid City, SD 57701
Who else practices at this address →
Pennington County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Mayo Medical School (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,696
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Mayo Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
SD license 4088
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Monument Health Rapid City Hospital Rapid City, SD
- Monument Health Spearfish Hospital Spearfish, SD
- Monument Health Sturgis Hospital Sturgis, SD
- Monument Health Custer Hospital Custer, SD
- Chadron Hospital Chadron, NE
Medical groups
- Monument Health Rapid City Hospital Inc (564 clinicians)
- Monument Health Network Inc (160 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,696
- Services billed
- 3,201
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 850 | 739 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 470 | 468 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 177 | 65 |
| Established patient office or other outpatient visit, 30-39 minutes | 150 | 134 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 124 | 121 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 123 | 121 |
| Ultrasound study of arm and leg arteries | 119 | 115 |
| Ultrasound of both sides of head and neck blood flow | 117 | 116 |
| Ultrasound of leg arteries or artery grafts | 112 | 105 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 110 | 110 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $498 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $151 |
|---|---|
| Boston Scientific Corporation | $125 |
| Medtronic, Inc. | $122 |
| Abiomed | $99.98 |
| Food and Beverage | $498 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $27,965 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and…
AstraZeneca Pharmaceuticals LP - BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.